Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRVI Stock Forecast 2026-2027
$5.04
Current Price
$1.86B
Market Cap
Buy 5
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to MRVI Price Targets
+19.0%
To High Target of $6.00
+19.0%
To Median Target of $6.00
-0.8%
To Low Target of $5.00
MRVI Price Momentum
+4.3%
1 Week Change
+3.9%
1 Month Change
+121.1%
1 Year Change
+55.1%
Year-to-Date Change
-3.3%
From 52W High of $5.21
+153.3%
From 52W Low of $1.99
📊 TOP ANALYST CALLS
Did MRVI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Maravai is one of their latest high-conviction picks.
Latest MRVI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, MRVI has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $6.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $5.04, the median forecast implies a 19.0% upside. This outlook is supported by 5 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRVI Analyst Ratings
5
Buy
3
Hold
0
Sell
MRVI Price Target Range
Low
$5.00
Average
$6.00
High
$6.00
Current: $5.04
Latest MRVI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRVI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $5.50 |
| Dec 15, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 12, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Aug 12, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 13, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 13, 2025 | Baird | Neutral | Maintains | $N/A | |
| Mar 25, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 21, 2025 | UBS | Neutral | Maintains | $N/A | |
| Mar 3, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Feb 26, 2025 | Baird | Neutral | Downgrade | $N/A | |
| Dec 5, 2024 | Goldman Sachs | Sell | Downgrade | $N/A | |
| Nov 14, 2024 | Wolfe Research | Peer Perform | Initiates | $N/A | |
| Nov 8, 2024 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 8, 2024 | William Blair | Market Perform | Downgrade | $N/A | |
| Nov 8, 2024 | Baird | Outperform | Maintains | $N/A | |
| Oct 8, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Aug 27, 2024 | Wells Fargo | Overweight | Initiates | $N/A | |
| Aug 16, 2024 | RBC Capital | Outperform | Reiterates | $N/A | |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | Downgrade | $N/A | |
| Aug 8, 2024 | Goldman Sachs | Neutral | Maintains | $N/A |
Maravai Lifesciences Holdings Inc. (MRVI) Competitors
The following stocks are similar to Maravai based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Maravai Lifesciences Holdings Inc. (MRVI) Financial Data
Maravai Lifesciences Holdings Inc. has a market capitalization of $1.86B with a P/E ratio of 28.4x. The company generates $204.73M in trailing twelve-month revenue with a -51.1% profit margin.
Revenue growth is +40.5% quarter-over-quarter, while maintaining an operating margin of +1.1% and return on equity of -41.0%.
Valuation Metrics
Market Cap
$1.86B
Enterprise Value
$1.05B
P/E Ratio
28.4x
PEG Ratio
-0.3x
Price/Sales
9.0x
Growth & Margins
Revenue Growth (YoY)
+40.5%
Gross Margin
+51.2%
Operating Margin
+1.1%
Net Margin
-51.1%
EPS Growth
+40.5%
Financial Health
Cash/Price Ratio
+22.3%
Current Ratio
5.9x
Debt/Equity
85.4x
ROE
-41.0%
ROA
-6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Maravai Lifesciences Holdings Inc. (MRVI) Business Model
About Maravai Lifesciences Holdings Inc.
What They Do
Provides critical biotechnology products and services.
Business Model
The company operates within the biotechnology and life sciences sector by producing nucleic acids and biologics, which are vital for drug development, diagnostics, and molecular testing. It generates revenue through the synthesis and modification of nucleic acids, particularly focusing on innovative mRNA technology crucial for vaccine and therapy development.
Additional Information
Maravai Lifesciences is instrumental in supporting scientific research and has played a key role in accelerating vaccine and treatment development, demonstrating its significance in the biopharmaceutical market. The company is committed to fostering scientific innovation and provides essential tools for researchers and healthcare institutions globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
416
CEO
Mr. Bernd Brust
Country
United States
IPO Year
2020
Website
www.maravai.comMaravai Lifesciences Holdings Inc. (MRVI) Latest News & Analysis
Latest News
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
5 days ago
Quick Summary
Maravai LifeSciences Holdings, Inc. has secured a $150 million term loan and a $30 million revolving credit facility to refinance existing obligations, supported by $98.5 million in cash.
Why It Matters
Maravai LifeSciences' new credit agreement enhances liquidity and financial flexibility, allowing for debt repayment and potential growth investments, which may positively influence future performance and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences upgraded to Buy due to restructuring and improved guidance. 2026 revenue forecast raised to $205–$215M; adjusted EBITDA to $30–$32M, with TriLink segment growing 15% YoY.
Why It Matters
Maravai's upgrade to Buy signals improved financial health and growth potential, with strong revenue guidance and cost savings likely to enhance shareholder value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Maravai LifeSciences (NASDAQ: MRVI) will participate in the Jefferies Global Healthcare Conference on June 4, 2026, featuring CFO Raj Asarpota in a fireside chat at 12:50 p.m. ET.
Why It Matters
Maravai LifeSciences' participation in a major investor conference signals engagement with the investment community, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences Holdings, Inc. (MRVI) has released its Q1 2026 earnings call transcript, detailing financial performance and company developments.
Why It Matters
The Q1 2026 earnings call for Maravai LifeSciences provides insights into financial performance and future guidance, impacting stock valuations and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Maravai LifeSciences Q1 Earnings Call Highlights
1 month ago
Quick Summary
Maravai LifeSciences (NASDAQ: MRVI) reported strong Q1 fiscal 2026 results, with growth from its TriLink segment and steady contributions from Cygnus, aided by last year's restructuring actions.
Why It Matters
Maravai LifeSciences' strong Q1 results indicate growth and effective restructuring, suggesting potential for continued profitability and stability, which can enhance investor confidence and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Maravai LifeSciences (NASDAQ: MRVI) reported Q1 2026 revenue of $65.8M, a net loss of $6.4M, and positive free cash flow of $4.2M. Adjusted EBITDA was $20.3M.
Why It Matters
Maravai's Q1 results show solid revenue and a return to positive free cash flow, indicating improved financial health and potential for growth, which can enhance investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MRVI Stock
What is Maravai Lifesciences Holdings Inc.'s (MRVI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Maravai Lifesciences Holdings Inc. (MRVI) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $5.00.
Is MRVI stock a good investment in 2026?
According to current analyst ratings, MRVI has 5 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRVI stock?
Wall Street analysts predict MRVI stock could reach $6.00 in the next 12 months. This represents a 19.0% increase from the current price of $5.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Maravai Lifesciences Holdings Inc.'s business model?
The company operates within the biotechnology and life sciences sector by producing nucleic acids and biologics, which are vital for drug development, diagnostics, and molecular testing. It generates revenue through the synthesis and modification of nucleic acids, particularly focusing on innovative mRNA technology crucial for vaccine and therapy development.
What is the highest forecasted price for MRVI Maravai Lifesciences Holdings Inc.?
The highest price target for MRVI is $6.00 from at , which represents a 19.0% increase from the current price of $5.04.
What is the lowest forecasted price for MRVI Maravai Lifesciences Holdings Inc.?
The lowest price target for MRVI is $5.00 from at , which represents a -0.8% decrease from the current price of $5.04.
What is the overall MRVI consensus from analysts for Maravai Lifesciences Holdings Inc.?
The overall analyst consensus for MRVI is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are MRVI stock price projections?
Stock price projections, including those for Maravai Lifesciences Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:20 AM UTC